Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zirabev (PF-06439535) vs Avastin in Advanced Non-Squamous NSCLC
NCT02364999Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-bvzr in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Objective Response Rate at 19 weeks. Started Apr 2015; status: completed.
02
Drugs
bevacizumab-bvzr
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02364999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364999.